

- Neuropathy (*Cont.*):
 pain in, 60, 89–90, 94–95
 peroneal, 463e-4, 463e-5f, 2683, 2692
 proximal femoral, 463e-5, 463e-5f
 radial, 463e-4, 463e-5f, 2691
 sacral, 274
 sciatic, 2692
 sensory deficits in, 161
 trigeminal, 2646–2647
 ulnar, 463e-4, 463e-5f, 1124, 2683, 2691
 Neuropathy, ataxia, retinitis pigmentosa (NARP) syndrome, 85e-6, 85e-6t, 451e-3t
 Neuropeptide Y, 415e-2
 Neuroprotective agents, 2563, 2616
 Neurosarcoidosis, 40e-4f, 441e-11–15f, 909t, 2208. *See also* Sarcoidosis
 Neurostimulation therapy, 2596
 Neurosyphilis
 clinical features of, 105, 163, 898–899, 907t, 1135–1136, 2607
 in congenital syphilis, 1137
 diagnosis of, 1135–1136, 1138t
 in HIV infection, 1259
 imaging in, 441e-3–5f
 treatment of, 1139, 1139t
 vs. viral meningitis, 892
 Neurotensin, 559t
 Neurotransmitter(s), 265e-4, 444e-2–4, 444e-3t
 Neurotrophic factors, 444e-7, 444e-7t
 Neutral protamine Hagedorn (NPH) insulin, 2411, 2411t
 Neutral theory of community assembly, 86e-6
 Neutron (η) particles, 263e-1
 Neutropenia, 413, 417
 acute, 417–418
 in cancer patient, 103e-3t, 103e-23–25. *See also* Cancer, infections in
 chronic, 423
 cyclic, 126, 237, 418
 diagnosis of, 423
 drug-induced, 417–418, 418t
 enterocolitis associated with, 488, 1099, 1797–1798, 1798f
 etiology of, 418t
 febrile, 103e-23, 490, 490f, 1047
 hereditary, 418
 in HIV infection, 1262
 in HSCT recipient. *See* Hematopoietic stem cell transplantation (HSCT), complications of
 refractory, 669t. *See also* Myelodysplasia in sepsis/septic shock, 1756, 1757t
 severe congenital, 2104, 2105f
 skin manifestations of, 76e-12f
 in SLE, 2129t, 2131
 treatment of, 423
 in viral hepatitis, 2016
 Neutrophil(s), 413
 abnormalities of
 chronic granulomatous diseases. *See* Chronic granulomatous diseases (CGDs)
 granule disorders, 419, 420t
 inherited disorders, 420t
 leukocyte adhesion disorders, 419, 420t
 neutropenia. *See* Neutropenia
 phagocyte activation disorders, 420t, 421
 in adaptive immunity, 372e-7t
 apoptosis of, 416
 in asthma, 1673
 circulating pools of, 415–417, 416f
 hypersegmented, 81e-3f
 in innate immunity, 372e-7t, 372e-8, 372e-15t
 marginated, 415–416, 416f
 marrow release of, 415–417
 maturation of, 413–415, 414f
 morphology of, 414f
 in peripheral blood smear, 81e-1–2
 senescent, 416
 shift to the left, 413
 in shock, 1747
 travel through pulmonary capillaries, 417f
 Neutrophil-activating protein-2 (NAP-2), 372e-12t
 Neutrophil bands, 415, 415f
 Neutrophil chemotactic factor (NCF), 372e-15t
 Neutrophil count, 417, 2754t, 2755t
 Neutrophil extracellular traps (NETs), 1753
 Neutrophil gelatinase associated lipocalin (NGAL), 1808
 Neutrophil granules
 disorders of, 419, 419t
 primary (azurophil), 415
 secondary (specific), 415
 toxic granulations, 415
 Neutrophilia, 413, 418–419, 418t
 Nevirapine
 action of, 1278
 adverse effects of
 cutaneous, 362, 381, 1278
 fever, 138
 hepatotoxicity, 1258, 2030
 in HIV infection, 1274t
 SJS or TEN, 46e-1f, 383, 1278. *See also* Stevens-Johnson syndrome (SJS); Toxic epidermal necrolysis (TEN)
 drug interactions of, 42t
 for HIV infection, 1274t, 1278
 molecular structure of, 1276f
 resistance to, 1278, 1279f
 Nevoid basal cell carcinoma syndrome. *See* Gorlin's syndrome (nevoid basal cell carcinoma syndrome)
 Nevomelanocytic nevus, 339f
 Nevus
 atypical, melanoma and, 493
 dysplastic, 76e-7f, 493–494, 493f
 melanocytic, 493–494
 nevomelanocytic, 76e-6f, 339f
 oral, 240t
 Nevus depigmentosus, 359
 Newborn(s). *See* Neonate(s)
 New daily persistent headache. *See* Headache, new daily persistent
 New York Heart Association (NYHA), classification of cardiovascular disease, 1439–1440, 1440t, 1501, 1501t, 1581t
 New York virus, 1308t
 Next-generation sequencing, 83e-3, 85e-4, 447, 769t
 NF1. *See* Neurofibromatosis type 1 (NF1)
 NF1 gene mutations
 action of, 603, 2343
 in CNS tumors, 599t, 603–604
 in juvenile myelomonocytic leukemia, 135e-6
 in melanoma, 496
 in neurofibromatosis 1, 2331
 in pheochromocytoma/paraganglioma, 2334, 2334f
 in pNETs, 562, 562t
 in soft tissue sarcomas, 119e-1
 tumors associated with, 101e-6t
 NF2. *See* Neurofibromatosis type 2 (NF2)
 NF2 gene mutations, 101e-6t, 599t, 604
 NF- κ B. *See* Nuclear factor- κ B (NF- κ B)
 NF- κ B essential modulator. *See* NEMO (NF- κ B essential modulator)
 NGAL (neutrophil gelatinase associated lipocalin), 1808
 Ngari virus, 1308t
 NGF (nerve growth factor), 444e-7t
 Niacin (vitamin B₃), 96e-4. *See also* Nicotinic acid
 deficiency of. *See* Pellagra
 functions of, 96e-2f, 96e-4
 metabolism of, 96e-4
 parenteral requirement for, 98e-5t
 recommended intake of, 95e-2t
 structure of, 96e-2f
 toxicity of, 96e-4
 Nicardipine
 adverse effects of, 1589t, 2218t
 for hypertension in subarachnoid hemorrhage, 1787
 for hypertensive emergencies, 1627, 1627t
 for ischemic heart disease, 1589, 1589t
 Niche site, stem cells, 89e-2
 Nickel allergy, 76e-2f, 345
 Nickel exposure, 472e-3, 477t, 502, 506
 Niclosamide, 246e-5t, 246e-11
 Nicoladoni-Branham sign, 1647
 Nicorandil, 1590
 Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, 416
 Nicotine, 444e-4, 465e-5t, 473e-10t, 2729. *See also* Smoking
 Nicotine replacement therapy, 507, 1705
 Nicotinic acid. *See also* Niacin (vitamin B₃)
 adverse effects of, 462e-19, 462e-20t, 2447, 2448t
 for lipoprotein disorders, 291e-6, 2447, 2448t
 for metabolic syndrome, 2454
 Nicotinic agonists, 473e-10t
 NIDDM (non–insulin-dependent diabetes mellitus). *See* Diabetes mellitus (DM), type 2
 Niemann-Pick disease, 432e-3t, 432e-5, 436e-7f, 451e-4t
 Nifedipine
 adverse effects of, 237, 253, 1589t
 for altitude illness, 476e-2t, 476e-4
 for chilblain, 478e-5
 for ciguatera poisoning, 2742
 dosage in liver disease, 37
 drug interactions of, 246e-6t
 for ergot alkaloid overdose/poisoning, 473e-8t
 for hypertension, 1624t, 1625, 2644
 for hypertension in pregnancy, 46
 for ischemic heart disease, 1589, 1589t
 overdose/poisoning with, 473e-9t
 for Raynaud's phenomenon, 1649, 2168f
 Nifurtimox
 action of, 246e-11
 adverse effects of, 246e-5t, 246e-11, 1396, 1560
 for Chagas disease, 1266, 1395–1396, 1560
 pharmacology of, 246e-11
 Night blindness, 96e-1t, 96e-6, 1946t
 Nightshade, 473e-9t
 Nijmegen breakage syndrome, 375e-1, 2109
 Nikolsky's sign, 134, 370, 959, 960f
 Nil lesion. *See* Minimal change disease
 Nilotinib
 action and targets of, 102e-3, 102e-5t, 103e-16, 103e-17t
 adverse effects of, 103e-17t, 692
 for CML, 691–692, 691t
 genetic variations in response to, 39t, 102e-16
 Nilutamide, 585
 Nimesulide, 338
 Nimodipine, 1787, 2597
 Nintedanib, 2164
 Nipah virus, 894
Nippostrongylus brasiliensis infection, 372e-8
 NIS (sodium iodide symporter), 372e-24t, 2284, 2284t
 NIS gene mutations, 2284
 Nisoldipine, 1589t
 Nissen fundoplication, 1908
 Nit(s), 2745–2746
 Nitazoxanide
 action of, 246e-11
 adverse effects of, 246e-5t
 for *C. difficile* infection, 860t, 861
 for *Cryptosporidium* infections, 1407
 for *Giardia* infections, 1406
 for *H. nana* infections, 1434
 pharmacology of, 246e-11
 in pregnancy and lactation, 246e-5t
 Nitisinone, 434e-5
 Nitrates
 action of, 1588
 adverse effects of, 1603
 dietary
 esophageal cancer and, 532
 gastrointestinal cancer and, 534, 534t
 for heart failure, 1509, 1608
 interaction with phosphodiesterase type 5 inhibitors, 43, 328, 1596, 1603
 for ischemic heart disease, 1588, 1588t
 long-acting, 1588